By analyzing the mRNA expression levels of F-box proteins in a larger AML patient cohort (GSE1159), we found that FBXO22 had higher expression in human AML than that in healthy samples, and ranked among the top candidates in all F-box proteins available in this cohort (Additional file 2: Fig. S1A), which was also supported by three other cohorts from AML patients (GSE13159, GSE7186 and GSE48173) (Fig. 1A and Additional file 2: Fig. S1B). This evidence concerns the gene FBXO22 and acute myeloid leukemia.